Table 3.
Time to onset and resolution of all-grade immune-related adverse events based on cancer types
| Lung cancer | Melanoma | |
|---|---|---|
| All categories | ||
| No. of patients with irAE | 800 (10.0) | 4,359 (18.3) |
| Time to onset (wk) | 4.7 (4.7–5.7)a) | 6.1 (5.7–7.6)a) |
| No. of patients with irAE | 502 (76.9) | 3,222 (80.5) |
| Time to resolution (wk) | 4.0 (2.7–9.4) | 4.4 (3.4–6.9) |
| Skin | ||
| No. of patients with irAE | 270 (19.4) | 1,496 (40.8) |
| Time to onset (wk) | 4.7 (2.9–5.7) | 4.0 (2.6–5.7) |
| No. of patients with resolution | 178 (76.7) | 1,026 (72.6) |
| Time to resolution (wk) | 9.4 (4.3–10.1) | 10.9 (5.1–22.1) |
| Gastrointestinal | ||
| No. of patients with irAE | 226 (16.2) | 1,294 (35.3) |
| Time to onset (wk) | 4.5 (4.4–22.4) | 6.3 (4.6–7.6) |
| No. of patients with resolution | 186 (86.5) | 1,217 (94.3) |
| Time to resolution (wk) | 2.7 (2.3–2.9) | 2.9 (2.4–3.1) |
| Hepatic | ||
| No. of patients with irAE | 74 (5.3) | 542 (14.8) |
| Time to onset (wk) | 8.0 (2.0–9.0) | 8.9 (6.1–9.0) |
| No. of patients with resolution | 56 (83.6) | 491 (90.6) |
| Time to resolution (wk) | 3.3 (2.0–4.0)a) | 5.1 (4.4–6.1)a) |
| Endocrine | ||
| No. of patients with irAE | 107 (7.7) | 749 (20.4) |
| Time to onset (wk) | 11.2 (8.9–13.3) | 8.9 (8.0–10.2) |
| No. of patients with resolution | 18 (52.9) | 258 (53.6) |
| Time to resolution (wk) | 10.4 (10.4–10.4) | 29.1 (13.9–54.3) |
| Pulmonary | ||
| No. of patients with irAE | 25 (4.7) | 77 (3.1) |
| Time to onset (wk) | 27.9 (4.8–27.9)a) | 10.1 (8.7–10.1)a) |
| No. of patients with resolution | 16 (84.2) | 69 (89.6) |
| Time to resolution (wk) | 5.9 (5.9–5.9) | 6.3 (3.0–7.0) |
| Renal | ||
| No. of patients with irAE | 17 (3.2) | 70 (2.8) |
| Time to onset (wk) | 8.2 (8.2–17.8)a) | 13.9 (9.7–15.7)a) |
| No. of patients with resolution | 6 (54.5) | 54 (77.1) |
| Time to resolution (wk) | 10.5 (10.5–10.5)a) | 2.3 (2.1–10.5)a) |
| Hypersensitivity/Infusion reaction | ||
| No. of patients with irAE | 16 (3.0) | 66 (3.1) |
| Time to onset (wk) | 0.2 (0.2–1.8)a) | 3.3 (2.2–6.1)a) |
| No. of patients with resolution | 10 (100) | 59 (89.4) |
| Time to resolution (wk) | 0.1 (0.1–0.1) | 0.1 (0.1–0.2) |
| Neurologic | ||
| No. of patients with irAE | 65 (7.5) | 20 (1.7) |
| Time to onset (wk) | 4.0 (4.0–7.1)a) | 13.1 (10.4–13.1)a) |
| No. of patients with resolution | 32 (49.2) | 15 (75.0) |
| Time to resolution (wk) | 28.7 (28.7–28.9)a) | 8.0 (0.7–11.6)a) |
Values are presented as number (%) or median (95% confidence interval). irAE, immune-related adverse event.
a)
p < 0.05 between the comparison of lung cancer and melanoma.